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tion, but 76.2% thought that the objective was to control phar-
maceutical spending. Most PCP’s (87.1%) declared that their
prescribing criteria provided enough control and that mecha-
nisms such as IVP are not necessary in medicines used in preva-
lent chronic diseases managed in primary care such as T2DM,
hence, 75.4% of PCP’s support their withdrawal. CONCLU-
SIONS: PCP’s believe that clinical criteria are enough to decide
on the appropriate treatment for T2DM, and that other control
mechanisms such as IVP are mainly focused on cost containment
purposes.
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OBJECTIVES: To assess therapy change, discontinuation, 
and insulin use among type-2 diabetic patients newly treated
with metformin (MF) or sulfonylurea (SU) monotherapy.
METHODS: Type-2 diabetic patients ≥30 years old who started
MF or SU monotherapy from January, 1997 to November, 2000
and had not received any hypoglycemic agents (HAs) within one
year prior to therapy initiation were identiﬁed from a UK general
practice (GP) database. At least one subsequent prescription of
HAs within one year after monotherapy initiation was required
for inclusion. Cox proportional hazards model, adjusted for
baseline patient characteristics and co-morbid conditions, was
used to estimate the likelihood of initiating insulin. RESULTS:
Among the 3857 eligible patients, 59.4% (40.4%) of them
started with SU (MF) monotherapy. For the SU (MF) group,
57.6% (50.8%) of them were male and the mean age was 67.5
(63.0) years. Those receiving MF were more likely to be women
(49.1% vs. 42.4%, p < 0.001), obese (16.2% vs. 6.70%, p <
0.001) and with dyslipidemia (28.5% vs. 23.8%, p < 0.001).
Mean duration of follow-up for the SU (MF) group was 25.1
(24.6) months. Therapy change was found in 19% (27%),
whereas therapy discontinuation was found in 24% (18%) of
the SU (MF)—treated patients. Initiation of insulin were 10.7%
(95%CI: 9.05%–12.4%) and 8.80% (95%CI: 6.76%–10.8%)
for the SU and MF groups, respectively. After controlling for con-
founders, the MF group had a lower hazard of initiating insulin
(Adjusted Hazard Ratio = 0.58, 95%CI: 0.45–0.75) compared
to the SU group. CONCLUSIONS: In this cohort of type-2 dia-
betic patients managed by GP’s in the UK who were newly
treated with MF or SU monotherapy, therapy change and dis-
continuation were common within a year. Almost 10% of them
initiated insulin during the average of a 2 year follow-up period.
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OBJECTIVES: People suffering from type-2 diabetes who fail on
monotherapy with metformin or sulphonylurea should receive
glitazones instead of injective insulin. Patients report a poor pref-
erence for insuline treatment because of its burden on their
quality of life. Glitazones could represent a more appropriate
treatment for them. Nowadays in Italy, glitazones are approved
for hospital use only. We describe the drug utilization of glita-
zones (rosiglitazone and pioglitazone), and relationship with
their potential use. METHODS: The expected number of type-
2 diabetic patients who could be treated with glitazones was cal-
culated analyzing a large database of diabetic patients. Patient
candidates for glitazones were those with an unsatisfactory gly-
caemic control using metformin or sulphonylurea, given at 
the highest dose tolerated by patients, obese (BMI > 30), with
haemoglobin A1c > 8%), without heart failure and liver diseases.
We obtained IMS Health data on sales of glitazones in Italy
during 2003 (365 days). These data were turned into Deﬁned
Daily Dose (DDD)/1000 inhabitants day, by means the formula:
distributed DDD/(population ¥ reference days) ¥ 1000.
RESULTS: The number of patients eligible for treatment with
glitazones was about 23,000. The expected use of glitazones (to
treat all eligible patients) was 0.4025 DDD/1000 inhab. day.
During the evaluated period, 0.0507 DDD/1000 inhab. day of
rosiglitazone and 0.0257 DDD/1000 inhab. day of pioglitazone
were distributed. Altogether, 0.0764 DDD/1000 inhab. day were
used in Italy. CONCLUSIONS: Distributed glitazones can treat
about 19% of eligible diabetic patients. The reasons of this poor
use could be the availability of glitazones only through the hos-
pital, and the limitation of hospital expenditure for drugs. Eligi-
ble patients who do not receive glitazones risk being treated with
injective insuline, with a negative burden on their quality of life.
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The JNC-7 and ADA recommend a goal BP of <130/80mmHg
in diabetes mellitus (DM) patients. Clinical trials suggest most
DM patients require ≥2 antihypertensive medications to achieve
BP goal. OBJECTIVES: Compare differences in BP and health-
care costs by CCB type (dihydropyridine [DHP] vs. (nondihy-
dropyridine [NDHP]) added to an antihypertensive regimen.
Proportion of patients tested for proteinuria was also assessed.
METHODS: Administrative claims data were obtained from
Western and Southeastern US health plans. Patients were identi-
ﬁed (N = 5551) with DM and HTN initiated on CCB therapy
from January 1, 2000 through June 30, 2002, with eligibility 6
months prior and 1 year post-index, no CCB prescriptions within
6 months pre-index date, and medication possession ratio >50%
in the 1 year post-index period. Costs attributable to DM or
HTN were analyzed. A random sample was targeted for medical
chart review. Testing for proteinuria was identiﬁed from both
claims and medical charts. RESULTS: Majority of patients initi-
ated on CCB received other antihypertensive medications; 86%
and 76% in the DHP and NDHP groups, respectively. The
NDHP group had lower annual attributable costs ($1637 [95%
CI, $1479–$1813] vs. $1989 [95% CI, $1823–$2170]; P <
0.004). A total of 313 medical charts were reviewed (DHP = 242,
NDHP = 71). Both groups had similar pre- and post-index BP
values; mean changes in SBP and DBP were not statistically sig-
niﬁcant between groups. Percentages of patients achieving BP
goal were low in both groups; <25% achieved SBP goal of <130
mmHg, and 36%–37% achieved DBP goal of <80mmHg. Less
than 45% of patients were tested for proteinuria during the study
period. CONCLUSIONS: Patients initiated on an NDHP
attained similar BP reductions compared to DHP at lower total
costs. Opportunities exist for more aggressive management of BP
and testing for proteinuria in DM patients with HTN.
